KRAS and neoplasm: ELI-002 2P, a cancer vaccine targeted against KRAS mutations, showed safe and effective T-cell responses in a phase 1 trial including 25 patients, indicating a reduction in tumor biomarkers and prolonged relapse-free survival in immunotherapy-resistant pancreatic and colorectal tumors [135].